BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vaizey CJ, Gibson PR, Black CM, Nicholls RJ, Weston AR, Gaya DR, Sebastian S, Shaw I, Lewis S, Bloom S, Gordon JN, Beale A, Arnott I, Campbell S, Fan T. Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. Frontline Gastroenterol 2014;5:183-9. [PMID: 28839768 DOI: 10.1136/flgastro-2013-100409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
2 Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol 2020;20:18. [PMID: 31964359 DOI: 10.1186/s12876-020-1164-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. Front Public Health 2021;9:675523. [PMID: 34268287 DOI: 10.3389/fpubh.2021.675523] [Reference Citation Analysis]
4 Rasmussen B, Haastrup P, Wehberg S, Kjeldsen J, Waldorff FB. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol 2020;55:656-63. [PMID: 32442051 DOI: 10.1080/00365521.2020.1768282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tripathi K, Dong J, Mishkin BF, Feuerstein JD. Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. Clin Exp Gastroenterol 2021;14:343-51. [PMID: 34511961 DOI: 10.2147/CEG.S237653] [Reference Citation Analysis]
6 Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri JC, DiBonaventura MD. Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient Rep Outcomes. 2018;2:62. [PMID: 30547275 DOI: 10.1186/s41687-018-0088-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Brookes MJ, Waller J, Cappelleri JC, Modesto I, DiBonaventura MD, Bohm N, Mokgokong R, Massey O, Wood R, Bargo D. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. BMJ Open Gastroenterol 2020;7:e000456. [PMID: 32938582 DOI: 10.1136/bmjgast-2020-000456] [Reference Citation Analysis]
8 Dignass A, Waller J, Cappelleri JC, Modesto I, Kisser A, Dietz L, DiBonaventura M, Wood R, May M, Libutzki B, Bargo D. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ 2020;23:415-27. [PMID: 31858853 DOI: 10.1080/13696998.2019.1707210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Langley PC. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). Innov Pharm 2020;11. [PMID: 34007634 DOI: 10.24926/iip.v11i3.3330] [Reference Citation Analysis]